Aerogen, Lyomark ink inhaled surfactant deal

Aerogen and Lyomark Pharma said today that they inked a deal to develop an inhaled surfactant treatment for respiratory distress syndrome in pre-term infants. The pact calls for the duo to combine a compound called AP-002, a nasally inhaled surfactant based on a combination of Lyomark’s Alveofact bovine lung surfactant and Aerogen’s PDAP nasal delivery technology. Aerogen will develop the drug-device combo and the companies will cooperate on commercialization and distribution, they said. Get the full story at our sister site, Drug Delivery Business News. The post Aerogen, Lyomark ink inhaled surfactant deal appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Respiratory Aerogen Ltd. lyomarkpharma Source Type: news